DP 9149
Alternative Names: DP-9149Latest Information Update: 18 Dec 2024
Price :
$50 *
At a glance
- Originator Deciphera Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action EIF2AK4 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 23 Oct 2024 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2024)
- 11 Jun 2024 Deciphera Pharmaceuticals has been acquired by Ono Pharmaceutical
- 14 Apr 2023 Pharmacodynamics data from a preclinical studies in solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)